Will Insurance Cover Zepbound for Sleep Apnea? 2025-2026 Update

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Tirzepatide (Zepbound) received FDA approval for moderate-to-severe OSA in adults with obesity in December 2024
• Most commercial plans added OSA coverage during 2025 formulary updates; coverage is not universal
• Prior authorization typically requires documented AHI 15+ and BMI 30+; some plans add PAP history requirements
• The OSA indication creates a parallel coverage path that can apply even when obesity-criteria coverage paths are blocked
• Medicare and Medicaid coverage have been slower and uneven; companion article AEO-3586 covers Medicare specifically

Direct answer

Many commercial insurance plans cover Zepbound for moderate-to-severe obstructive sleep apnea (AHI 15+) following the December 2024 FDA approval. Coverage is not universal, prior authorization is generally required, and documentation typically includes sleep study results, BMI, and sometimes CPAP history. Medicare Part D and Medicaid coverage have been slower and vary by plan and state. The OSA indication has expanded coverage options for many patients with obesity plus OSA who previously found GLP-1 medications inaccessible, but the system is still settling into the new approval.

Table of contents

1. What changed in December 2024
2. How commercial plans responded
3. Standard prior authorization criteria
4. OSA as comorbidity versus OSA as parallel indication
5. The AHI 15 threshold and what happens below it
6. What documentation actually works
7. The CPAP relationship
8. Medicare and Medicaid status
9. Appeals after denial
10. Cash and self-pay alternatives
11. Decision framework
12. FAQ
13. Sources

What changed in December 2024

The FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024. The approval was based on the SURMOUNT-OSA trial program (Malhotra et al., NEJM 2024), which showed AHI reduction of approximately 27-30 events per hour at 52 weeks alongside weight loss of 18-20%.

The label addition specified:

• Moderate-to-severe obstructive sleep apnea (AHI 15+)
• Adults with obesity (BMI 30+)
• Used alongside reduced-calorie diet and increased physical activity
• Same dose titration as the existing obesity indication (2.5 → 15 mg weekly)

The approval did not create a new dose or formulation. It added OSA as an indication on the existing Zepbound label. Mounjaro (same molecule, type 2 diabetes indication) did not receive the OSA expansion.

The regulatory action had downstream effects on coverage. Plans that had been treating Zepbound exclusively as an obesity medication now had to decide whether to add OSA-specific coverage paths, and how strictly to enforce documentation requirements.

How commercial plans responded

The commercial plan response unfolded over 2025 in roughly three waves.

Wave 1 (Q1 2025): early adopters. Several large commercial plans (some Blue Cross Blue Shield affiliates, parts of UnitedHealthcare's commercial book, Cigna) added OSA-specific Zepbound coverage in the first quarter, generally with prior authorization requirements aligned with the SURMOUNT-OSA trial criteria.

Wave 2 (Q2-Q3 2025): formulary updates. Most major commercial plans added Zepbound under the OSA indication during their 2025 mid-year or annual formulary updates. Prior authorization criteria became more standardized: AHI 15+, BMI 30+, sometimes a PAP history requirement.

Wave 3 (Q4 2025-Q1 2026): refinement. Plans began differentiating between OSA-pathway coverage and obesity-pathway coverage. Some plans tightened criteria after initial broad coverage; others expanded.

As of May 2026, the rough patterns:

• Approximately 70-80% of commercial plans cover Zepbound for OSA with appropriate prior authorization
• Approval rates with proper documentation are high (often 80%+ on first submission)
• Some plans require sleep medicine specialist involvement; others accept primary care diagnosis
• Plans that previously excluded obesity medications often added Zepbound-OSA as a narrow exception

The numbers above are general patterns. Specific plan coverage varies. Always verify your specific plan's policy before assuming coverage.

Standard prior authorization criteria

Common Zepbound-OSA prior authorization elements as of May 2026:

Criterion	Typical requirement
OSA diagnosis	Sleep study (polysomnography or home sleep test) with AHI 15+
BMI threshold	30 or higher
Age	18 or older
Sleep study recency	Often within last 2-5 years
PAP history	Variable; some plans require attempt or intolerance, some do not
Lifestyle documentation	Variable; some plans require evidence of lifestyle counseling or program enrollment
Specialist involvement	Variable; some plans require sleep medicine specialist or sleep clinic referral
Reauthorization	Most plans require continued evidence of treatment response (weight loss, AHI improvement) for renewal at 6-12 months

The criteria are not uniform. The most reliable approach is to call the plan's prescription coverage line, ask for the specific Zepbound-OSA prior authorization criteria, and gather the listed documentation before submission.

OSA as comorbidity versus OSA as parallel indication

The OSA approval changed coverage in two distinct ways.

OSA as comorbidity for obesity-tier coverage. Wegovy and Zepbound were already FDA-approved for obesity at BMI 27+ with at least one weight-related comorbidity. OSA is one of the standard comorbidities (along with hypertension, dyslipidemia, type 2 diabetes). The OSA-specific Zepbound approval reinforced OSA's status as a qualifying comorbidity at the lower BMI tier.

OSA as a parallel indication. The December 2024 approval created a Zepbound-specific OSA indication independent of the obesity criteria. For some plans, this means Zepbound can be approved for OSA even when obesity-criteria coverage is blocked (for example, if the plan excludes obesity medications generally but covers OSA medications).

The practical implication: if your plan denied Zepbound under the obesity criteria in 2024, the OSA indication may open a new coverage path in 2026. Resubmission with OSA-specific documentation is often productive.

The AHI 15 threshold and what happens below it

The FDA Zepbound OSA indication specifies "moderate-to-severe" OSA, defined as AHI 15 or higher. Patients with mild OSA (AHI 5-15) are technically outside the labeled indication.

Coverage paths for mild OSA:

• Obesity-with-comorbidity (BMI 27+). Mild OSA can serve as the comorbidity for Wegovy or Zepbound coverage at BMI 27+. The path is the standard obesity indication, not the OSA-specific indication.
• Obesity alone (BMI 30+). If BMI is 30+, OSA severity does not matter; standard obesity criteria apply.
• OSA pathway with documentation of clinical significance. Some plans accept mild OSA with significant daytime symptoms, comorbid cardiovascular disease, or other complicating factors. This is plan-specific and often requires more clinical documentation.

Mild OSA in normal-weight patients without comorbidities is the hardest case. Most plans will not cover Zepbound in this population. Treatment options include CPAP, oral appliances, positional therapy, or surgical interventions.

What documentation actually works

From plan and provider experience over 2025, the documentation that improves approval odds for Zepbound-OSA:

• Sleep study report explicitly stating AHI and OSA severity classification
• BMI measured in clinic, not self-reported
• Clinical note explicitly stating: "Tirzepatide initiated for FDA-approved indication of moderate-to-severe obstructive sleep apnea with obesity"
• PAP history: device, pressure settings, adherence data, or documented intolerance
• Patient willingness to continue or initiate weight management (lifestyle counseling, nutrition support, etc.)
• If applicable, comorbidities (hypertension, type 2 diabetes, established CV disease)

"Failed lifestyle modification" alone rarely works for any GLP-1 prior authorization, OSA or otherwise. Plans look for structured documentation, not a checkbox.

If your provider's office is unfamiliar with the OSA pathway, they may default to submitting under the obesity indication. Asking specifically for OSA-pathway submission can help, particularly if the obesity pathway has been denied before.

The CPAP relationship

CPAP coverage is separate from Zepbound coverage. CPAP devices, supplies, and replacements are covered under durable medical equipment (DME) benefits, while Zepbound is covered under prescription drug benefits.

Most plans continue CPAP coverage during Zepbound treatment, since the medication takes months to produce meaningful AHI reduction. Stopping CPAP requires:

• Documented weight loss (typically 10%+)
• Repeat sleep study (without CPAP) showing AHI below treatment threshold
• Symptom assessment confirming no significant daytime sleepiness
• Plan approval, in some cases, before DME coverage stops

Patients sometimes ask whether plans push for CPAP discontinuation to save money once Zepbound is started. This is generally not the case; plans cover both during titration because that aligns with clinical guidelines.

Some plans audit CPAP usage data (modern devices report adherence to the cloud). Patients with low CPAP adherence may face increased scrutiny on whether continued DME coverage is appropriate. The push tends to be toward documenting adherence or transitioning to alternative therapy, not toward forcing Zepbound to replace CPAP.

Medicare and Medicaid status

Medicare Part D coverage of Zepbound for OSA varies. Some Part D plans added the indication during 2025; others did not. CMS's historical position is that Medicare does not cover weight-loss medications under standard Part D rules, even though the OSA indication is technically a treatment indication rather than a weight-loss indication.

The legal and regulatory interpretation continues to evolve. A separate FormBlends article (AEO-3586) covers Medicare OSA coverage specifically.

State Medicaid programs vary widely. Some added Zepbound-OSA coverage in 2025; others have not. Each state operates its own preferred drug list and prior authorization criteria. Coverage tends to be more restrictive than commercial plans.

VA and TRICARE coverage exists but with stricter criteria than most commercial plans.

Appeals after denial

If Zepbound is denied for OSA, the appeal process generally has three stages:

1. Written appeal. Your provider's office submits documentation. Most plans require this within 60-180 days of denial. Include sleep study, BMI documentation, clinical note specifically referencing the FDA OSA indication, and any additional supporting information.
2. Peer-to-peer review. Your prescriber requests a conversation with the plan's medical director. Success rate is higher than written appeals alone. Sleep medicine specialists doing peer-to-peer often have stronger leverage than primary care, particularly for borderline cases.
3. External review. If internal appeals fail, every state offers external review through the state insurance department. An independent reviewer evaluates the case; the decision is binding on the plan.

Common reasons for Zepbound-OSA denial and how to address them:

Denial reason	Appeal approach
AHI not documented in claim	Submit full sleep study report with AHI clearly stated
BMI below 30	Pursue obesity-with-comorbidity path (BMI 27+ with OSA as comorbidity) for Wegovy or Zepbound
"Not medically necessary"	Peer-to-peer review with sleep specialist; document FDA indication language
"PAP therapy not tried"	Document attempt, intolerance, or contraindication; some plans require this
Plan excludes weight-loss medications	Argue OSA-pathway submission, not weight loss; cite FDA OSA-specific indication

Cash and self-pay alternatives

Without coverage, Zepbound retail is approximately $1,050 per month for the auto-injector. Eli Lilly's Zepbound Self-Pay Pharmacy program offers single-dose vials at lower cost (approximately $499-650 per month depending on dose).

Manufacturer savings cards for commercially insured patients can reduce out-of-pocket cost substantially:

• Zepbound Savings Card: as low as $25 per month for commercially insured patients with coverage
• Without commercial coverage: variable, typically $499-650 self-pay
• Government insurance patients (Medicare, Medicaid, TRICARE) are not eligible for the savings card

Compounded tirzepatide through telehealth platforms typically runs $300-450 per month. This is the cash alternative many patients use when insurance denies. Compounded options are not FDA-approved and have not been specifically studied for OSA. The mechanism is the same, but regulatory status differs.

Decision framework

If you have moderate-to-severe OSA (AHI 15+) and BMI 30+: Your case fits the FDA Zepbound indication squarely. Pursue insurance coverage through the OSA pathway. Most commercial plans will approve with appropriate documentation.

If you have mild OSA (AHI 5-15) and BMI 30+: Pursue the standard obesity indication (Wegovy or Zepbound under BMI 30+). The OSA-specific pathway does not apply, but the obesity pathway does.

If you have moderate-to-severe OSA and BMI 27-30: Pursue obesity-with-comorbidity coverage (OSA as the comorbidity). Standard Wegovy or Zepbound criteria apply. The OSA-specific Zepbound indication technically requires BMI 30+, though some plans interpret more flexibly.

If you have OSA and Medicare: Check your specific Part D plan. Coverage is variable. See AEO-3586 for more detail.

If you've been denied: Appeal. Peer-to-peer review with a sleep specialist is the highest-yield path.

If insurance coverage is unavailable: Cash, Lilly Self-Pay Pharmacy, or compounded tirzepatide through telehealth are the practical alternatives.

FAQ

Will insurance cover Zepbound for sleep apnea? Most commercial plans now cover it with prior authorization. Documentation typically includes AHI 15+ and BMI 30+. Medicare and Medicaid coverage varies.

What documents do I need? Sleep study report, BMI documentation, clinical note referencing the FDA OSA indication, and sometimes PAP history.

What if my AHI is below 15? The OSA-specific indication requires AHI 15+. For mild OSA, the standard obesity pathway (BMI 30+, or 27+ with OSA as comorbidity) is the alternative.

Does the OSA approval change how obesity criteria work? Yes. OSA can serve as the qualifying comorbidity at BMI 27+, and Zepbound has a separate OSA coverage path that can apply when obesity-criteria coverage is blocked.

Does Medicare cover it for OSA? Some Part D plans added coverage in 2025; many did not. See AEO-3586 for more detail.

Does Medicaid cover it for OSA? Varies by state. Each state Medicaid program operates its own preferred drug list.

What if my plan denies the claim? Appeal. Written appeal first, then peer-to-peer review, then external review through your state insurance department.

Can I still use CPAP while on Zepbound? Yes, and most patients should during the first 12-18 months. CPAP coverage is separate from Zepbound coverage and continues during treatment.

How long does prior authorization take? Most plans process within 7-14 days. Expedited review (24-72 hours) is available if delay would harm health.

Does Wegovy cover OSA now too? Not specifically; the OSA indication is Zepbound-only. Wegovy covers OSA through the obesity-with-comorbidity pathway.

What if I started Zepbound under obesity and now want OSA coding? Your provider can resubmit under the OSA indication. This can be useful if your plan tightens obesity coverage but maintains OSA coverage.

How is reauthorization handled? Most plans require evidence of treatment response at 6-12 months (weight loss, sometimes repeat sleep study showing AHI improvement). Document everything for renewal.

Sources

1. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM. 2024.
2. FDA Drug Label. Zepbound (tirzepatide) Prescribing Information. Updated December 2024 to include OSA indication.
3. FDA Approval Letter. Zepbound for Moderate-to-Severe OSA in Adults with Obesity. December 20, 2024.
4. American Academy of Sleep Medicine. Clinical Practice Guideline for the Treatment of Adult Obstructive Sleep Apnea. 2019 update.
5. CMS Coverage Determinations. Part D Coverage of GLP-1 Medications. 2024-2025.
6. National Association of Insurance Commissioners. External Review Process Overview. 2025.
7. Eli Lilly. Zepbound Savings Card Terms and Conditions. 2026.
8. Eli Lilly. Zepbound Self-Pay Pharmacy Program. 2024-2026.
9. Peppard PE et al. Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology. 2013.
10. Patil SP et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: AASM Guideline. 2019.
11. Romero-Corral A et al. Interactions between obesity and obstructive sleep apnea. Chest. 2010.
12. ICD-10-CM Official Guidelines for Coding and Reporting. FY 2026.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed providers. We do not adjudicate insurance claims or guarantee any specific coverage outcome. Information about coverage reflects publicly available plan and CMS information as of May 2026; specific plan policies vary and change.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved for any indication and has not been studied specifically for OSA. It is prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. Compounded medications are not interchangeable with brand-name products.

Results Disclaimer. Coverage decisions, prior authorization criteria, and pricing vary by plan, state, employer, and policy year. Approval in one case does not predict approval in another. Verify current criteria with your specific plan.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by these companies or any government health program.